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Pediatric acute renal failure in southwestern Nigeria.
Background. Acute renal failure (ARF) was investigated to
determine the prevalence of ARF clinical types, etiology, co-
morbidities, and outcome in Nigerian children.
Methods. Consecutive cases of ARF admitted from March,
1994 through February, 2003 were prospectively studied. Infor-
mation were obtained concerning the following: age, gender,
body surface area, early (within 48 hours of onset of ARF) or
late (>48 hours of onset of ARF) presentation, admission du-
ration, etiology, comorbidities, urine volume/day, dialysis need,
reasons for considering dialysis, laboratory investigations, and
outcome in each patient. Histopathologic reports of percuta-
neous renal and surgical biopsies, as well as autopsy specimens,
were reviewed.
Results. There were 78 boys and 45 girls (M:F, 1.73:1); mean
age was 6.28 ± 4.0 years. A portion of patients presented
early (46.3%), while 53.7% presented late. Oliguric (63.41%),
anuric (20.33%), and nonoliguric (16.26%) ARF were the clin-
ical types seen. Dialysis requirement was significantly higher
in oliguric (P < 0.005) and anuric (P < 0.005) than nono-
liguric ARF. Primary and secondary etiologies accounted for
29% and 71% of ARF cases, respectively. Renal Burkitt’s
lymphoma (47.2%), glomerulonephritis (27.8%), nephrotic
syndrome (16.7%), hemolytic uremic syndrome (5.5%), and
acute tubulointerstitial nephritis (2.8%) were primary etiolo-
gies. Plasmodium falciparum malaria (42.53%), septicemia
(28.73%), hypovolemia (11.49%), and obstructive uropathy
(8.05%) were major secondary etiologies. Financial constraints
on the part of parents of patients, as well as inadequate and/or
lack of dialysis equipment, were major inhibitions to effective
management of the patients; in fact, 6 patients took voluntary
discharge due to inability to afford the cost of treatment. Mor-
tality risk factors were late presentation [odds ratio (OR) 3.5,
P < 0.001], dialysis eligibility (OR 3.8, P < 0.001), nondialysis
(OR 23.1, P = 0.00004), primary etiology (OR 2.6, P < 0.025),
and presence of ≥2 comorbidities (OR 2.9, P < 0.025); overall
mortality rate was 46.2%.
Conclusion. These results show that many of the causes of
ARF in our patients are preventable; it should be possible to
reduce morbidity due to ARF through purposive preventive
measures.
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Acute renal failure (ARF) is a serious disorder of kid-
ney functions with significant morbidity and mortality in
children. Morbidities such as electrolytes derangement,
fluid overload, sepsis, neurologic abnormalities, hyper-
tension, metabolic acidosis, disordered coagulation, and
endocrine dysfunction are common [1–3]. Mortality rate
in some series ranged from 16% to 63.3% [4–6]. Data on
ARF from the West African (WA) subregion to which
Nigeria belongs are rather few [7–10] and infrequent com-
pared to other parts of the world [1–6, 11–14].
ARF in WA presents unique features that are peculiar
to developing countries where cultural practices, religious
beliefs, poverty, and unstable health policies due to polit-
ical instability significantly influence clinical presentation
and outcome of diseases; causes of ARF are largely due
to preventable diseases like gastroenteritis, malaria, and
typhoid septicemia [7–10]. ARF is a common pediatric
problem in WA but largely under-reported due to paucity
of pediatric nephrologists. This study was an attempt
at reporting our data on ARF in Nigerian children. The
objectives were to determine the prevalence of ARF clin-
ical types, etiology, comorbidities, and outcome in a Nige-
rian pediatric nephrology unit with ARF incidence of 10
new cases per million children population per year [15].
METHODS
Consecutive cases of ARF admitted from March, 1994
through February, 2003 were prospectively studied. Infor-
mation obtained were those contained in a programmed
data form; these included age, gender, body surface area,
early or late presentation to the hospital, admission du-
ration, etiology of ARF, associated comorbidities, urine
volume per day, dialysis need, indications for consider-
ing dialysis, hematology, plasma and urinary biochemi-
cal investigations, as well as eventual clinical outcome
in each patient. Histopathologic reports of percutaneous
renal and surgical biopsies and autopsy specimens were
reviewed.
Early presentation
This category comprises patients who presented to
the hospital within 48 hours of onset of acute renal
insufficiency.
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Late presentation
This category comprises patients who presented more
than 48 hours after onset of renal insufficiency.
Classification of ARF
Oluguric acute renal failure (OARF). Defined as uri-
nary output less than 300 mL/m2 /day in addition to
sudden onset of progressive plasma accumulation of ni-
trogenous wastes and electrolytes imbalance in a previ-
ously healthy child.
Nonoliguric ARF (NOARF). Defined as sudden onset
of deteriorating plasma biochemical status in spite of a
urinary output that is greater than 300 mL/m2/day without
the use of diuretics.
Anuric ARF (ANARF). Defined as acute deteriora-
tion of plasma biochemical status, as well as production
of a urine volume that is less than 1 mL/kg/day in the
absence of urinary tract obstruction.
Investigations
The following investigations were carried out to deter-
mine etiology of ARF in the patients:
Hematology/oncology. Blood film appearance; full
blood counts; platelets counts; glucose-6-phosphate de-
hydrogenase enzyme assay; direct and indirect Coombs
tests; bleeding time; clotting time; prothrombin time;
partial thromboplastin time et kaolin; tumor aspirate
(in suspected Burkitt’s lymphoma cases) for cytology;
bone marrow aspirate and cerebrospinal fluid were ob-
tained for cytology to either confirm or exclude presence
of Burkitt’s cells.
Microbiology. Thin and thick blood films for malaria
parasites; blood culture for aerobic and anaerobic bacte-
ria; urine microscopy, culture and sensitivity (midstream
or suprapubic specimen); stool microscopy, culture and
sensitivity.
Biochemistry. Urinalysis for proteinuria, reducing
substances, pH, specific gravity, hemoglobinuria, and
bilirubin; plasma for electrolytes, urea, uric acid, cre-
atinine, phosphate, calcium, proteins, cholesterol and
bilirubin; urinary sodium, potassium, phosphate, calcium,
protein and creatinine.
Histopathology. Renal biopsy, surgical biopsy, au-
topsy specimens.
Radiology. Renal ultrasound for bipolar diameter,
transverse diameter and cortical thickness; urinary blad-
der (including ureters) ultrasound; micturating cys-
tourethrogram in patients with obstructive uropathy.
Conservative management of oligoanuria
Fluid intake was restricted to 300 to 400 mL/m2/day
(insensible loss) plus urine volume the previous 24 hours.
Salt intake (sodium) was restricted to 0.5 to 1.0 mmol/
kg/day usually not exceeding 10 to 20 mmol/day irrespec-
tive of age. Occasionally, salt-free diet was prescribed in
very bad patients. Protein intake was usually 0.5 to 1.0 g/
kg/day. Carbohydrate was liberalized; where oral intake
was not feasible, 10% dextrose water infusion was pre-
scribed. Fats/oils were taken as palm oil in the cooked
food. Hyperkalemia was conservatively treated with 10%
calcium gluconate intravenously (IV) at 0.3 mL/kg/dose,
followed by IV salbutamol, 125 to 250 lg stat, repeated
6 hourly, and 8.4% sodium bicarbonate, 2 to 3 mL/
kg IV bolus. These were then followed by IV solu-
ble insulin 0.25 U/kg 6 hourly (until satisfactory potas-
sium level was achieved) in addition to glucose infusion,
4 g/kg over a 24-hour period. Plasma potassium was
monitored 2 to 4 hourly in patients treated with
insulin/glucose infusion. Dialyses were prescribed for pa-
tients whose plasma potassium levels were >6.5 mmol/L.
Conservative management was maintained, however, in
patients who could not afford dialysis or to be dialyzed
for some other reasons. Hypertension was treated with
IV furosemide, 2 to 4 mg/kg/day, especially in patients
with acute glomerulonephritis; in other cases, severe hy-
pertension was treated with IV hydralazine, 0.2 to 0.5
mg/kg repeated 6 hourly until blood pressure dropped to
upper limit of normal for age when oral a-methyldopa
was introduced at 25 to 50 mg/kg/day. Captopril (0.25 to
0.6 mg/kg/day in 2 divided doses), amilodipine (0.15 to
0.3 mg/kg/day), or lacidipine (0.06 to 0.12 mg/kg/day)
were prescribed in a few patients who could afford them.
Eligibility criteria for dialysis
Clinical criteria for dialysis included pulmonary
edema, congestive heart failure, symptomatic severe ane-
mia, severe hypertension not responsive to drugs, uremic
symptoms (e.g., bleeding diathesis, pericarditis, seizures,
altered sensorium, nausea, vomiting), and fluid overload.
Biochemical
Biochemical criteria included metabolic acidosis
(plasma bicarbonate <15 mmol/L), hyperkalaemia
(plasma potassium >6.5 mmol/L), plasma urea >25
mmol/L, plasma creatinine >300 to 500 lmol/L in chil-
dren <5 years of age, and >500 lmol/L in patients
>5 years of age, and hyperphosphatemia (phosphate>1.7
mmol/L).
Urinary output
Urinary output was monitored by urethral catheter-
ization in: (1) all anuric patients; (2) patients with
obstructive uropathy; (3) patients <5 years of age because
of bedwetting; and (4) unconscious patients. Catheters
were changed weekly and discontinued once the patients
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developed urinary tract infection (UTI). Those with UTIs
were promptly treated with ceftriaxone parenterally.
Analyzed hematologic and biochemical data
These included haematocrit, sodium, potassium, bicar-
bonate, calcium, phosphate, urea, uric acid, creatinine,
urinary/plasma creatinine ratio (Ucr/Pcr), and fractional
excretion of filtered sodium (FeNa,%).
FeNa was determined from UNa/Ucr × Pcr/PNa × 100.
UNa and PNa are urinary and plasma concentrations of
sodium, respectively; Ucr and Pcr are urinary and plasma
concentrations of creatinine, respectively.
Statistical analysis
Statistical mean ± SD were compared using Student
t test; where indicated, chi-square and Fisher exact tests
were carried out to compare proportions for statistical
significance. Values of P < 0.05 was regarded as statisti-
cally significant.
Association between a risk factor and mortality from
ARF was tested by determining the odds ratio (OR) from
the cross-product ratio in a simple 2 × 2 chi-square test
table; the 95% confidence interval (CI) was determined
from Miettinen’s test-based approximation using the
chi-square (95% CI = OR(1±1·96/X) [16]), 1.96 being the
5% point of the standard normal distribution, X =
√
X2.
RESULTS
Among the 123 patients studied, 78 (63.40%) were boys
and 45 (36.60%) were girls; male/female ratio was 1.73:1.
59 (48%) were less than 5 years old while 64 (52%) were
over 5 years old. Overall mean age ± SD was 6.28 ± 4.0
(0.05 to 15.0) years. While 57 (46.30%) presented early,
66 (53.70%) presented late to the hospital.
OARF (63.41%), ANARF (20.33%), and NOARF
(1626%) were the three clinical types of ARF seen. A
breakdown of their clinical characteristics showed that
there were 50 boys and 28 girls among the OARF clinical
type; their mean age ± SD was 6.8 ± 3.81 (0.05 to 15)
years. However, among the ANARF clinical type there
were 15 boys and 10 girls; their mean age was 5.8 ± 3.6
(0.5 to 12) years. There were 13 boys and 7 girls among the
NOARF; their mean age was 6.13 ± 4 (0.9 to 13) years.
Of the 123 patients, 66 required dialysis while 57 did not.
Among those who required dialysis, OARF, ANARF, and
NOARF accounted for 40, 23, and 3 cases, respectively.
Thirty-eight OARF, 2 ANARF, and 17 NOARF cases re-
quired no dialysis.
Clinical and laboratory features warranting dialysis
in eligible patients are shown in Table 1. The need for
dialysis was significantly higher between OARF (P <
0.005) and ANARF (P < 0.005) compared to NOARF
Table 1. Frequency of clinical and laboratory features warranting
dialysis in eligible patients (N = 66)
Dialysis indications Patient number (%)
Clinical N = 27
Bleeding diathesis/anemic heart failure 9 (33.33)
(AHF)
Severe hypertension (SHTN)/congestive 7 (25.93)
heart failure (CHF)/seizures/coma
SHTN not responsive to antihypertensive 4 (14.81)
drugs
AHF/uremia/seizures 3 (11.11)
SHTN/pulmonary edema 2 (7.41)
Fluid overload 2 (7.41)
Laboratory N = 25
Hyperkalemia (≥6.5 mmol/L) 6 (24)
Metabolic acidosis 5 (20)
(bicarbonate <15 mmol/L)
Metabolic acidosis/hyperkalemia/ 5 (20)
hyperphosphatemia
Severe azotemia 4 (16)
(urea ≥25 mmol/L)
Hyperphosphatemia (phosphate >1.7 3 (12)
mmol/L)
Severe azotemia/hyperkalemia 2 (8)
Clinicolaboratory N = 14
Severe azotemia/seizures/coma 5 (35.71)
Severe azotemia/bleeding diathesis (BD) 3 (21.43)
Severe azotemia/SHTN/pulmonary edema 3 (21.43)
Metabolic acidosis/uremic pericarditis/BD 3 (21.43)
patients; similarly, the need for dialysis was significantly
higher in ANARF than OARF (< 0.005) patients.
Primary and secondary etiologies of ARF are sum-
marized in Table 2. Primary and secondary etiolo-
gies accounted for 36 (29.0%) and 87 (71.0%) cases,
respectively. Renal Burkitt’s lymphoma (RBL) and P. fal-
ciparum malaria (PFM) were, respectively, the leading
primary and secondary causes of ARF in the patients.
Plasma and urinary data obtained within 72 hours of
admission of the patients are shown in Tables 3 and 4,
respectively.
Mean hematocrits for OARF, ANARF, and NOARF
were 22.15 ± 6.1%, 17.0 ± 4.2%, and 15.8 ± 7.3%, re-
spectively; all had similar degrees of anemia, P > 0.50.
Comorbidity patterns are shown in Table 5; anemia was
present in all patients. It was the sole comorbidity in 34 of
123 (27.64%) patients and occurred in combination with
other comorbid conditions in the remaining 89 (72.36%)
patients. Hypertension was present in 30 patients; hy-
pertension was due to RBL (N = 17), poststreptococal
acute glomerulonephritis (N = 9), fluid overload due to
faulty fluid giving sets (N = 2), and nephrotic syndrome
(N = 2).
Outcome of patients
Six patients (5%) discharged against medical advice
due to financial constraints; all 6 had OARF, and 5 were
<5 years old while 1 was >5 years old. The remain-
ing 117 patients were managed until they were either
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Table 2. Etiology of acute renal failure in Nigerian children
Etiology Patient number
(%)
Primary N = 36 (29)
Renal Burkitt’s lymphoma 17 (47.2)
Glomerulonephritis
PSAGNa 9 (25)
MPGNb 1 (2.8)
Nephrotic syndrome 6 (16.7)
Hemolytic uremic syndrome 2 (5.5)
Acute tubulointerstitial nephritis 1 (2.8)
Secondary N = 87 (71)
Plasmodium falciparum malaria 37 (42.53)
Septicemia 25 (28.73)
Hypovolemia
Gastroenteritis 9 (10.34)
Severe hemorrhage 1 (1.15)
Obstructive uropathy
Posterior urethral valves 5 (5.75)
Urinary bladder rhabdomyosarcoma 2 (2.3)
Intravascular hemolysis
G-6-PD deficiencyc 4 (4.6)
Autoimmune hemolytic anemia 2 (2.3)
CTHDd
Purpura fulminans 1 (1.15)
Thrombotic thrombocytopenic purpura 1 (1.15)
aPost-streptococcal acute glomerulonephritis.
bMembranoproliferative glomerulonephritis.
cGlucose-6-phosphate dehydrogenase deficiency.
dConsumptive thrombohemorrhagic disorder.
regularly discharged or demised. Of the 117 patients, 54
were <5 years old (survivors = 26 and nonsurvivors =
28) and 63 were >5 years old, with 37 survivors and 26
nonsurvivors. The difference was not significant (OR 1.5,
95% CI 1.3–3.0; P > 0.50). Fifteen of 51 (29.41%) and
39 of 66 (59.10%) patients who presented early and late,
respectively, to the hospital, demised. Late presentation
was significantly more than three times a mortality risk
factor (OR 3.5, 95% CI 1.6–7.5; P < 0.001).
All were admitted for a mean period of 16.02 ± 8.5 (0.5
to 44) days. Survivors among OARF spent 21.53 ± 8.4
[10 to 43] days on admission, while nonsurvivors spent
10 ± 10.10 (0.5 to 44) days. Among NOARF patients,
survivors spent 20.5 ± 7.1 [10 to 33] days, while nonsur-
vivors spent 16 ± 10.2 [5 to 25] days. The periods spent on
admission by survivors and nonsurvivors among ANARF
patients were 19.3 ± 10.1 [10 to 41] days and 5.13 ± 2.42
(1.0 to 9.0) days, respectively. All survivors spent similar
number of days on admission, P > 0.50.
Sixty-six patients were eligible for dialysis; however, 6
took voluntary discharge (mainly OARF), 10 were di-
alyzed, and the remaining 50 patients were managed
conservatively. Financial constraints, shortage and/or lack
of dialysis equipment, inadequate staff, and late pre-
sentation precluded dialysis treatment in those not di-
alyzed. Of the dialyzed patients, 7 were by peritoneal
dialysis (PD) and 3 by hemodialysis (HD). Twenty-
three (38.3%) dialysis-eligible patients survived, while 37
(61.7%) demised; among noneligible patients, 40 (70.0%)
survived while 17 (30%) demised. The difference was sig-
nificant, with the risk of mortality being almost 4 times
higher in dialysis-eligible than noneligible patients (OR
3.8, 95% CI 1.8–8.1, P < 0.001). Among dialyzed patients,
9 (90%) survived while 1 (10%) demised; and of the non-
dialyzed dialysis-eligible patients, 14 (28.0%) survived
while 36 (72.0%) demised (OR 23.1, 95% CI 4.4–122;
P = 0.00004). A comparison of etiology of ARF with out-
come revealed that of the 36 patients whose renal failure
was of primary origin, there were 13 survivors (12 OARF,
1 ANARF), 22 nonsurvivors (14 OARF, 8 ANARF),
and a case (OARF) of voluntary discharge. Among the
13 survivors, etiology in 3 was due to RBL (OARF), 7
(6 OARF, 1 ANARF) to glomerulonephritis (GN), and
1 each to nephrotic syndrome (NS), hemolytic uremic
syndrome (HUS), and acute tubulointerstitial nephritis
(ATIN); the latter 3 cases presented as OARF. However,
of the 22 nonsurvivors, etiology in 14 was due to RBL
(10 OARF, 4 ANARF), 3 to GN (1 OARF, 2 ANARF),
4 to NS (3 OARF, 1 ANARF), and 1 to HUS (ANARF).
On the other hand, there were 51 survivors (26 OARF,
17 NOARF, 9 ANARF) and 31 nonsurvivors (21 OARF,
3 NOARF, 7 ANARF) among the 87 patients whose
ARF was of secondary etiology. The remaining 5 patients
(OARF) took voluntary discharge. Of the 51 survivors,
etiology in 25 (13 OARF, 9 NOARF, 3 ANARF) was
due to P. falciparum malaria (PFM), 14 to septicemia
(4 OARF, 5 NOARF, 5 ANARF), 3 to gastroenteritis
(2 OARF, 1 ANARF), 1 to severe hemorrhage (OARF),
and 1 each (NOARF) to posterior urethral valves (PUV)
and urinary bladder rhabdomyosarcoma (UBR). Fur-
thermore, of the remaining 6 survivors’ etiology in 3
(OARF) was due to glucose-6-phosphate dehydroge-
nase deficiency (G-6-PD-), 2 to autoimmune hemolytic
anemia (1 OARF, 1 NOARF), and 1 to purpura ful-
minans (OARF). Of the 31 nonsurvivors, etiology in
9 (7 OARF, 2 ANARF) was due to PFM, 10 to septicemia
(7 OARF, 3 ANARF), 5 to gastroenteritis (3 OARF,
2 ANARF), 4 to PUV (2 OARF, 2 NOARF), and 1 each
to UBR (NOARF), G-6-PD- (OARF), and thrombotic
thrombocytopaenic purpura (OARF).
Of the 35 patients with primary ARF, 13 (37.0%)
survived while 22 (63.0%) demised; however, 50 of 82
(61.0%) cases of secondary ARF survived while 32
(39.0%) demised. The difference was significant (OR 2.6,
95% CI 1.2–5.7; P < 0.025).
Table 6 compares the outcome of 1 comorbidity with
≥2 comorbidities in each of the three ARF types. How-
ever, pooled data of 117 patients managed until regularly
discharged or demised, showed that patients with ≥2 co-
morbidities had significantly higher mortality than those
with 1 comorbidity (OR 2.9, 95% CI 1.2–6.9; P < 0.025).
Among OARF patients, 36 of 78 (46.0%) survived,
6 took voluntary discharge (8.0%), and 36 (46.0%)
demised. Ten of 25 (40.0%) ANARF patients survived
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Table 3. Plasma biochemical comparisons of clinical types of acute renal failure
P value for P value for P value for A
NOARFa NOARF versus OARFb OARF versus ANARFc ANARF versus
Plasma biochemistry Mean (SD) OARF Mean (SD) PANARF Mean (SD) NOARF
Sodium mmol/L 134.2 (4.6) <0.001 129.37 (6.0) <0.005 124.4 (7.15) <0.001
N = 20 N = 78 N = 25
Potassium mmol/L 3.85 (1.0) <0.05 4.38 (0.98) <0.001 5.7 (1.5) <0.001
N = 20 N = 78 N = 25
Bicarbonate mmol/L 19.2 (1.14) <0.02 18.45 (1.46) <0.001 17.3 (1.2) <0.001
N = 20 N = 78 N = 25
Calcium mmol/L 1.39 (0.21) <0.02 1.25 (0.18) <0.01 1.07 (0.28) <0.001
N = 16 N = 54 N = 21
Phosphate mmol/L 1.28 (0.23) <0.001 1.65 (0.44) <0.001 2.43 (0.80) <0.001
N = 17 N = 50 N = 23
Uric acid mmol/L 0.36 (0.13) <0.001 0.52 (0.18) <0.001 0.90 (0.18) <0.001
N = 15 N = 65 N = 23
Urea mmol/L 23.0 (12.0) >0.5 23.31 (10.25) >0.2 25.48 (12.12) >0.2
N = 20 N = 78 N = 25
Creatinine lmol/L 435 (249) <0.001 674.2 (311) <0.001 940.38 (314) <0.001
N = 20 N = 78 N = 25
aNonoliguric acute renal failure.
bOliguric acute renal failure.
cAnuric acute renal failure.
Table 4. Urinalysis data of anuric (ANARF), oliguric (OARF), and nonoliguric (NOARF) acute renal failure patients
ANARFa P value for OARFb P value for N0ARFb P value for
Mean ± (SD) ANARF versus Mean± (SD) OARF versus Mean ± (SD) ANARF versus
Urinary data N = 25 OARF N = 78 NOARF N = 20 NOARF
Urine volume 0.78 ± 0.07 – 173.1 ± 58.3 <0.001 432.3 ± 101.3 –
Sodium mmol/L 114.7 ± 26.1 <0.001 86.0 ± 38 <0.001 61.0 ± 21.2 <0.001
Creatinine lmol/L 3418.3 ± 1654.6 >0.1 2905.4 ± 920 <0.001 2133.1 ± 382 <0.001
Ucr/Pcr 3.7 ± 2.0 >0.5 3.5 ± 3.2 <0.05 5.3 ± 3.0 <0.05
FeNa % 26.1 ± 9 <0.001 15.7 ± 4.0 <0.001 8.6 ± 1.8 <0.001
aUrine volume expressed as mL/kg/day; volume not compared with OARF/NOARF due to non-uniformity of units.
bUrine volume expressed as mL/m2/day.
while 15 (60%) demised; 17 of 20 (85.0%) NOARF pa-
tients survived while 3 (15.0%) demised. There were
significantly more deaths between OARF (P < 0.005)
and ANARF (P < 0.005) compared to NOARF pa-
tients; mortality was, however, similar in both OARF and
ANARF patients, P > 0.50. Survivors between OARF
and ANARF were oliguric and anuric for 9.8 ± 4.7 (4.0 to
20.0) days and 9.5 ± 3.4 (4.0 to 15.0) days, respec-
tively. Plasma creatinine normalized, 13 ± 3.1 (9.0 to
18.0) days, 10.92 ± 4.2 (5.0 to 18.0) days, and 5.71 ±
2.1 (3.0 to 9.0) days postdiuresis in ANARF, OARF,
and NOARF, respectively. Diuresis duration before nor-
malization of plasma creatinine levels was significantly
shorter in NOARF compared to either OARF, P < 0.001,
or ANARF, P < 0.001; it was similar in both OARF and
ANARF, P > 0.20. Mean plasma creatinine levels at dis-
charge for OARF, ANARF, and NOARF were 68.55 ±
12.3 (50.0 to 98.0), 68.80 ± 16.10 (45.0 to 96.00), and
64.5 ± 16.23 (36.0 to 100.0) lmol/L, respectively. All val-
ues were similar, P > 0.50.
The overall mortality (N = 54) and survival (N = 63)
rates among the 117 patients managed until regularly dis-
charged or demised were 46.2% and 53.8%, respectively.
Twenty-one of 63 survivors were lost to follow-up, while
42 were regularly followed-up for 1.0 to 16.0 (3.6 ± 2.93)
months.
DISCUSSION
There is a general preponderance of boys over girls
with respect to ARF in some studies [4, 5, 17]. In our
series, ARF was almost two times as common in boys
than girls. The mean age of occurrence of ARF in this
study, 6.28 ± 4.0 years was found to be similar to that
reported in other studies [5, 12, 18], thus showing that
infants and young children are the most vulnerable to
ARF. Mortality has been particularly found to be much
higher in this age group [5, 19]. In this study, age below
5 years was not a significant mortality risk factor (OR 1.5,
P > 0.50) compared to earlier studies [5, 19] because all
cases of RBL were found in patients whose ages were
over 5 years; RBL alone, known to be associated with
poor prognosis [20], accounted for 54% of deaths in that
age group.
The majority of our patients (53.7%) presented late to
the hospital. This is similar to 48% found among Indian
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Table 5. Comorbid conditions in acute renal failure (ARF)
Total
Comorbidity patternsa OARFb NOARFc ANARFd (%)
Two comorbidities (N = 40)
Anemia plus:
Urinary tract
infection (UTI)
6 8 0 14 (35)
Congestive heart
failure (CHF)
6 2 2 10 (25)
Septicemia (SCM) 3 0 2 5 (12.5)
Hypertension (HTN) 1 1 3 5 (12.5)
Cerebral malaria 2 1 0 3 (7.5)
Aspiration
pneumonitis
2 0 0 2 (5)
Lobar pneumonia 1 0 0 1 (2.5)
Three comorbidities (N = 29)
Anemia plus:
Tumor lysis syndrome
(TLS), HTN
9 0 0 9 (31.03)
Bleeding diathesis
(BD), SCM
3 2 1 6 (20.69)
Pulmonary edema,
HTN
3 0 1 4 (13.80)
Paralytic ileus (PLI),
SCM
3 1 0 4 (13.80)
Seizures, coma 2 0 1 3 (10.34)
Uremic pericarditis,
CHF
2 0 1 3 (10.34)
Four comorbidities (N = 20)
Anemia plus:
TLS, HTN, seizures 4 0 4 8 (40)
Seizures, coma, HTN 3 0 1 4 (20)
Uremic pericarditis,
BD, CHF
2 0 2 4 (20)
Xerophthalmia (in
kwashiorkor
patients), SCM,
PLI
2 0 0 2 (10)
Peritonitis, BD, CHF 2 0 0 2 (10)
aOnly septicemic conditions that developed while on admission are tabulated;
etiologic data are excluded.
bOliguric ARF.
cNonoliguric ARF.
dAnuric ARF.
patients [5]. Most patients in this country would initially
try spiritualists, herbalists/diviners, and self-medication
on account of beliefs and poverty before seeking medical
opinion, usually when clinical status would have become
precarious. Like in the Indian study, late presentation was
found to be a risk factor for mortality in our series (OR
3.5, P < 0.001).
OARF (63.41%), ANARF (20.33%), and NOARF
(16.26%), as seen in this study, presented, respectively,
with variable severity of clinical and laboratory features
with significant impact on therapeutic intervention and
outcome. This prevalence pattern is at variance with those
of other studies. In one series, ANARF and OARF, re-
spectively, accounted for 53.6% and 46.4% [21]; in an-
other series, NOARF (60%) and OARF (40%) were
found [1]. Yet in another series, a different combina-
tion of OARF (65%) and NOARF (35%) was reported
[22]. These variations have significant impact on dialy-
sis requirement. Units with preponderance of NOARF
patients have little need for dialysis because of the mild
nature of the disease [1, 22]. Conversely, demand for dial-
ysis treatment was higher in the unit with large number
of ANARF and OARF patients [21]. In this study, OARF
and ANARF accounted for 95.45% of all dialysis-eligible
patients; the need for dialysis treatment was therefore sig-
nificantly higher, P < 0.005, in either OARF or ANARF
compared to NOARF.
Heart failure (due to either severe anemia or hyper-
tension), hyperkalemia, metabolic acidosis, and severe
azotemia occurring either solely or in combination with
other clinical entities, were major indications for dialysis
treatment in our patients. However, in Ghana [10] and
Morocco [4], deteriorating clinical status, fluid overload,
rapidly rising urea or plasma level ≥33 mmol/L, severe
hyperkalemia, and hypernatremia were major indications
for dialysis treatment. Only 10 of 60 (17%) dialysis-
eligible patients received dialysis treatment. This is
disturbingly low when compared with dialysis access rate
of 62% [10] and 100% [4, 12] reported in other countries.
In Nigeria, poor access to dialysis treatment is quite a
formidable problem [8, 15]. Financial constraints on the
parts of parents, shortage and/or lack of dialysis equip-
ment, inadequate staff, and late presentation, which had
earlier been reported from this center [15], continue to be
major reasons for nondialysis of eligible patients. Dialysis
eligibility (OR 3.8, P < 0.001) and nondialysis of eligible
patients (OR 23.1, P = 0.00004) were mortality risk fac-
tors in this study. Early dialysis treatment has been asso-
ciated with better prognosis in ARF patients [4, 11, 12].
All over the world, prevalences of primary and sec-
ondary etiologies of ARF vary from center to center. In
some centers, primary etiology predominates, account-
ing for 57% to 93% of cases [4, 12, 21, 23, 24]. In others,
secondary etiology predominates, accounting for 66% to
100% of cases [7, 10, 25]. In our series, secondary eti-
ology predominates, accounting for 71% of cases. These
are largely due to preventable diseases as in other West
African studies [7, 10]. In most of those centers where
ARF was mostly of primary origin, hemolytic uremic
syndrome (HUS) and acute glomerulonephritis (AGN)
lead [4, 12, 21]. HUS, largely reported to be the lead-
ing cause of ARF in children in developed countries and
South America [11, 12, 14, 26], is a rare etiologic entity in
Africa [4, 7–10], except in South Africa, where it occurs in
epidemic proportions [27]. This study further confirms
the rarity of HUS in Africa. Nigeria falls within latitude
15◦ North and South of the equator, where both Burkitt’s
lymphoma and malaria are endemic [28, 29]. It is, there-
fore, not surprising that RBL and PFM were, respectively,
the leading primary and secondary causes of ARF in our
series. It has been postulated that chronic malaria in-
fection causes immunosuppression, thereby causing ma-
lignant transformation of Epstein-Barr virus–infected
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Table 6. Relation between number of comorbidities and outcome of acute renal failure (N = 117)
Number of Outcome of 1 Outcome of ≥2
comorbidities comorbidity comorbidities
ARF types 1 ≥2 Survivors Nonsurvivors Survivors Nonsurvivors P value
OARFa 22 56 15 5 21 31 <0.01
N = 78
ANARFb 7 18 4 3 6 12 0.1987
N = 25
NOARFc 5 15 4 1 13 2 0.4605
N = 20
aOliguric acute renal failure; 6 of 78 patients discharged against medical advice. Therefore, their eventual outcome was not known.
bAnuric acute renal failure.
cNonoliguric acute renal failure.
lymphocytes to Burkitt’s lymphoma [30]. A confirmation
of this hypothesis could explain why RBL and PFM were,
respectively, the leading primary and secondary etiolo-
gies of ARF in this study; it could also mean that preven-
tive measures against malaria would significantly reduce
the frequency of ARF cases due to Burkitt’s lymphoma.
In this study, primary etiology was associated with higher
risk of mortality (OR 2.6, P < 0.025) than secondary
etiology largely because of the high number of deaths
recorded among the RBL patients (Table 3). This con-
trasts sharply with findings elsewhere, where secondary
etiologies were associated with significant mortality
[24, 31]. Etiology rather than ARF and its attendant bio-
chemical disorders, which are amenable to correction, has
been recognized as being more an important mortality
risk factor [13, 22]. It is instructive to note that gastroen-
teritis, which was the most common cause of ARF in some
series in this country [8], ranks a distant third (10.34%)
behind PFM (42.53%) in our series (Table 3). Aggres-
sive health education in the last 15 years, improved man-
agement of gastroenteritis by health workers, and better
understanding of the use and ready acceptability of salt-
sugar solution and oral rehydration salts by mothers of
patients in our catchment areas could have accounted
for this remarkable drop in incidence of gastroenteritis-
associated ARF.
Nephrotoxins, burns, and trauma that are commonly
associated with NOARF [1, 32] in children and adults
were not seen in this study; instead, malaria, septicemia,
posterior urethral valves, urinary bladder rhabdomyosar-
coma, and severe intravascular hemolysis were observed,
thus suggesting that causes other than nephrotoxins,
burns and trauma may cause NOARF.
Severity of biochemical disorders that normally occur
in ARF is dependent on the degree of renal damage.
Hyponatremia, metabolic acidosis, hypocalcemia, hy-
perphosphatemia, hyperuricemia, and hypercreatinemia
were found to be significantly more severe in OARF
and ANARF than NOARF (Table 4). This is in conso-
nance with findings from other studies [1, 21]. Urinary
sodium losses (sodium concentration and FeNa, Table 5)
were found to be significantly heavier in both ANARF
and OARF than NOARF. This is again similar to find-
ings from an earlier study [1]. Similarly, ANARF and
OARF patients exhibited poorer ability to concentrate
urine (Ucr/Pcr ratio <20) compared to NOARF.
Comorbidities are common features of childhood ARF
[1, 3] with significant contribution to mortality. The co-
morbid pattern in this study is of serious and frightening
kind; ARF coexisted with equally serious and sometimes
fatal morbidities like cerebral malaria, kwashiorkor, as-
piration pneumonitis, severe hypertension, heart failure,
peritonitis, paralytic ileus, and tumor lysis syndrome. The
comorbidities significantly influenced mortality in the pa-
tients (P < 0.025), with the mortality risk being almost
three times higher in those with 2 or more comorbidities.
This confirms earlier assertion that comorbidities, like
etiology, influence outcome more than ARF itself [13,
22]. This strongly suggests early detection and aggressive
management of comorbidities. NOARF had the lowest
comorbidity rate (17%) in this study compared to either
ANARF (20%) or OARF (63%). This is similar to the
findings of other workers [1]. While it is clear that comor-
bidities are inarguably associated with increased risk of
mortality in this and other studies, ARF in Southwestern
Nigeria and other parts of the world (especially the devel-
oped world) differ significantly in certain areas. For exam-
ple, ARF in Southwestern Nigeria presents an etiologic
pattern that is at variance with what is seen elsewhere;
HUS remains the dominant cause of ARF in developed
countries and South America [11, 12, 14, 26]. Unlike in
developed countries, ready access to dialysis treatment is
uncommon in Nigeria; in this series, majority (83%) of
our dialysis-eligible patients were not dialyzed due to a
number of factors earlier discussed. Furthermore, early
treatment is still not possible in a good number of our
patients due to late presentation in hospital.
Unlike in OARF and ANARF, recovery in NOARF
was significantly faster, P < 0.001, as plasma creatinine
concentration normalized within 5.71 ± 2.1 days of onset
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of diuresis. Survival was equally better in NOARF,
P < 0.005, than either OARF or ANARF. The overall
mortality rate of 46.2% was comparable to 41.5% [5],
46.9% [13], and 50% [25] mortality rates recorded in
other centers. It certainly could be reduced through (1)
close monitoring of all OARF and ANARF patients and
prompt accessibility to dialysis, (2) early detection and
management of comorbidities, (3) close monitoring of
dialysis-eligible patients, and (4) careful and slow induc-
tion of remission with low-dose cytotoxic drugs in RBL
patients with dialysis back-ups. Early presentation in
hospital is also expected to improve outcome. Given the
fact that the major causes of ARF in this series are pre-
ventable, it should be possible to reduce morbidity due
to ARF through purposive preventive measures.
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